|
|
Volumn 46, Issue 1, 2001, Pages 23-27
|
|
Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an International Consensus Meeting
a,b
|
|
Author keywords
Antibody panels; Consensus; Immunophenotyping; Leukemia; Lymphoma
|
|
Indexed keywords
ANTIBODY;
BIOCHEMICAL MARKER;
CD16 ANTIGEN;
CD19 ANTIGEN;
CD2 ANTIGEN;
CD20 ANTIGEN;
CD23 ANTIGEN;
CD3 ANTIGEN;
CD36 ANTIGEN;
CD4 ANTIGEN;
CD45 ANTIGEN;
CD5 ANTIGEN;
CD56 ANTIGEN;
CD7 ANTIGEN;
CD8 ANTIGEN;
COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;
HLA ANTIGEN;
REAGENT;
ACUTE LEUKEMIA;
ARTICLE;
B LYMPHOCYTE;
BLOOD DISEASE;
CANCER STAGING;
CELL LINEAGE;
DISEASE MARKER;
EVALUATION;
HUMAN;
LYMPHOMA;
LYMPHOPROLIFERATIVE DISEASE;
MEDICAL SOCIETY;
MEGAKARYOCYTE;
ORGANIZATION;
PATIENT MONITORING;
PHENOTYPE;
PLASMA CELL DYSCRASIA;
PRIORITY JOURNAL;
QUESTIONNAIRE;
T LYMPHOCYTE;
BIOLOGICAL MARKERS;
FLOW CYTOMETRY;
HEMATOLOGIC NEOPLASMS;
HUMANS;
IMMUNOPHENOTYPING;
LEUKEMIA;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
LYMPHOMA;
PLASMACYTOMA;
QUESTIONNAIRES;
|
|
EID: 0035864819
PISSN: 01964763
EISSN: None
Source Type: Journal
DOI: 10.1002/1097-0320(20010215)46:1<23::AID-CYTO1033>3.0.CO;2-Z Document Type: Article |
|
Times cited : (90)
|
|
References (8)
|
